Xenetic Biosciences, Inc. (XBIO)

US — Healthcare Sector
Peers: RNAZ  LABP  NEXI  ONCR  ZVSA  IMMX  PHIO  ATNF  NAVB  REVB  YS  GOVX  NBY  SONN  PALI  DRUG  VRAX  TNXP  ZURA  CYTO  ENVB 

Automate Your Wheel Strategy on XBIO

With Tiblio's Option Bot, you can configure your own wheel strategy including XBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol XBIO
  • Rev/Share 1.6748
  • Book/Share 3.3222
  • PB 0.903
  • Debt/Equity 0.0
  • CurrentRatio 8.2004
  • ROIC -0.7548

 

  • MktCap 4626420.0
  • FreeCF/Share -1.7249
  • PFCF -1.7392
  • PE -1.2612
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.5729

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
XBIO
Published: March 26, 2025 by: Accesswire
Sentiment: Neutral

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has entered into a Clinical Study Agreement (the "Agreement") to support an exploratory clinical study of Xenetic's systemic DNase I candidate, XBIO-015, in patients with relapsed/refractory osteosarcoma and Ewing sarcoma.

Read More
image for news Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

About Xenetic Biosciences, Inc. (XBIO)

  • IPO Date 2016-06-30
  • Website https://www.xeneticbio.com
  • Industry Biotechnology
  • CEO Mr. James F. Parslow
  • Employees 2
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.